Efficacy and safety of enzalutamide, abiraterone and cabazitaxel in post-docetaxel treatment of castration-resistant prostate cancer: meta-analysis data

Background. Castration-resistant prostate cancer (CRPC) is wide-spread severe disease in many regions of the world. Enzalutamide, abiraterone and cabazitaxel have been recently registered for the treatment of this condition.Objective: to perform indirect comparison of enzalutamide, abiraterone and c...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: P. V. Mazin, N. K. Mazina
Materialtyp: Artigo
Språk:Russo
Publicerad: ABV-press 2017-12-01
Serie:Onkourologiâ
Ämnen:
enzalutamide
abiraterone
cabazitaxel
castration-resistant prostate cancer
indirect comparisson
meta-analysis
overall survival
Länkar:https://oncourology.abvpress.ru/oncur/article/view/772
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk